Edesa Biotech, Inc.EDSANASDAQ
Loading
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q4 2025 | -8.23% |
| Q3 2025 | 30.51% |
| Q2 2025 | 93.90% |
| Q1 2025 | -52.51% |
| Q4 2024 | 881.85% |
| Q3 2024 | -88.42% |
| Q2 2024 | -23.72% |
| Q1 2024 | 66.98% |
| Q4 2023 | -26.11% |
| Q3 2023 | -7.04% |
| Q2 2023 | -29.66% |
| Q1 2023 | 7.43% |
| Q4 2022 | -24.34% |
| Q3 2022 | -60.55% |
| Q2 2022 | 49.45% |
| Q1 2022 | -22.99% |
| Q4 2021 | -4.28% |
| Q3 2021 | -7.54% |
| Q2 2021 | -44.02% |
| Q1 2021 | 478.07% |
| Q4 2020 | 19.47% |
| Q3 2020 | 0.95% |
| Q2 2020 | 127.49% |
| Q1 2020 | -4.77% |
| Q4 2019 | 9.59% |
| Q3 2019 | -4.20% |
| Q2 2019 | 33.85% |
| Q1 2019 | -20.10% |
| Q4 2018 | -5.44% |
| Q3 2018 | 6.91% |
| Q2 2018 | -5.81% |
| Q1 2018 | -21.74% |
| Q4 2017 | -2.47% |
| Q3 2017 | 20.67% |
| Q2 2017 | 62.79% |
| Q1 2017 | -28.53% |
| Q4 2016 | -30.32% |
| Q3 2016 | 40.70% |
| Q2 2016 | 52.10% |
| Q1 2016 | 7.00% |